Clinical trials: Systemic Light Chain Amyloidosis
- Condition Systemic Light Chain Amyloidosis
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Amyloidosis
Phase 1 Study of GSK2315698 in Healthy Japanese Subjects
This is the first study in which GSK2315698 will be administered in Japanese population. The primary objective of the study is to investigate safety and tolerability, pharmacokinetics, and pharmacodynamics after single…
- Trial name
- NCT02953808
- Testing
- GSK2315698
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Amyloidosis; Systemic
Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess…
- Trial name
- AT02-001 (NCT05521022)
- Testing
- AT-02
- Where
- 11 sites in United States, Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Attralus, Inc.
Amyloidosis
A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis
GSK3039294 has been developed in order to offer an orally available alternative to parenteral CPHPC (GSK2315698 [metabolite of GSK3039294]) for plasma serum amyloid P component (SAP) depletion prior to use of anti SAP monoclonal…
- Trial name
- NCT02603172
- Testing
- GSK3039294
- Where
- United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline